@article{Manso_Farina_Andreoni_Blasi_Conte_Fazii_Lombardi_Sanna_2014, title={Antifungal susceptibility testing of Aspergillus species complex in the Clinical Laboratory: how to do it, when to do it, and how to interpret it}, volume={29}, url={https://www.pagepressjournals.org/mm/article/view/4889}, DOI={10.4081/mm.2014.4889}, abstractNote={<p>The emergence of drug resistance in fungal pathogens has a profound impact on human health given limited number of antifungal drugs. Antifungal resistance in <em>Aspergillus</em> spp. infection can be encountered in the antifungal drug-exposed patient due to selection of intrinsically resistant species or isolates with acquired resistance belonging to species that are normally susceptible. Resistance to triazoles is not common in <em>Aspergillus</em> spp., however, triazole resistance in <em>A. fumigatus</em> appears to be increasing in several European countries in recent years and can be clinically relevant. The Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing have developed breakpoints and epidemiological cutoff values that are now established for <em>Aspergillus</em> spp. Clinical microbiology laboratories will be employed commercial susceptibility assays, rather than reference broth microdilution methods and comparative studies are particularly important.</p>}, number={2}, journal={Microbiologia Medica}, author={Manso, Esther and Farina, Claudio and Andreoni, Stefano and Blasi, Elisabetta and Conte, Marco and Fazii, Paolo and Lombardi, Gianluigi and Sanna, Silvana}, year={2014}, month={Dec.} }